EDISON EQUITY RESEARCH - TRIMEL PHARMACEUTICALS - ENDO LAUNCHES NATESTO

US partner Endo has launched Trimel’s Natesto in the c US$2bn US testosterone replacement therapy (TRT) market. Natesto is being positioned as the first and only nasal gel for hypogonadism, and is highlighted for its lower associated risk of testosterone transference.

Trimel is a Canadian specialty pharmaceutical company. Natesto and Tefina deliver testosterone through a bio-adhesive nasal gel drug delivery technology platform, for male hypogonadism and female orgasmic disorder (FOD), respectively. Estrace is marketed for HRT in Canada.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports

Acerus Pharmaceuticals (QB) (USOTC:ASPCF)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Acerus Pharmaceuticals (QB).
Acerus Pharmaceuticals (QB) (USOTC:ASPCF)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Acerus Pharmaceuticals (QB).